This content is in French.
Efficacy and safety of denosumab and teriparatide compared with oral bisphosphonates in the treatment of postmenopausal osteoporosis: a systematic review and meta-analysis
17 septembre 2024

Although bisphosphonates have traditionally been the cornerstone of pharmacological management of bone protection in patients, new evidence suggests that teriparatide and denosumab merit further investigation as potential first-line treatments. The optimal choice between denosumab, teriparatide and oral bisphosphonates for the treatment of postmenopausal osteoporosis remains a subject of debate and controversy within the scientific community.
Sign in to read the rest
Reserved for healthcare professionals, free registration.



